SIS
PTGX icon

Sound Income Strategies’s Protagonist Therapeutics PTGX Stock Holding History

Sound Income Strategies’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-156
Closed -$16.2K – 1907
2026
Q1 		$16.2K Sell
156
-128
-45% -$11.3K ﹤0.01% 1277
2025
Q4 		$23.3K Buy
+284
New +$23.2K ﹤0.01% 1090

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Sound Income Strategies's PTGX Position: Q2 2026 in Review

Sound Income Strategies sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 156 shares — an estimated $16.2K sold.

Sound Income Strategies first reported a position in PTGX in Q4 2025 and held it in 2 quarters. The position peaked at $23.3K in Q4 2025. 244 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Sound Income Strategies reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 156 Protagonist Therapeutics shares in Q2 2026, an estimated $16.2K.
  • Sound Income Strategies first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's Protagonist Therapeutics position peaked at $23.3K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.